IMCnyeso is well tolerated and, at doses ≥30 μg, induces pharmacodynamic changes consistent with T cell redirection. This study was registered at ClinicalTrials.gov (NCT03515551).

9 months ago

P1 data • Journal

HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)

IMCnyeso

almost2years

Modulation of TRPV4-mediated TNF-α expression in Müller glia and subsequent RGC apoptosis by statins. (PubMed, Exp Eye Res)

Cells were pretreated with simvastatin or lovastatin before GSK101...Herein, we showed that statins can modulate gliosis and TNF-α expression in Müller cells, protecting RGCs. These data further support the neuroprotective effect of statins, promoting them as a potential treatment for glaucoma.

almost 2 years ago

Journal

TNFA (Tumor Necrosis Factor-Alpha) • TRPV4 (Transient Receptor Potential Cation Channel Subfamily V Member 4)

IMCnyeso • lovastatin

over3years

Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers (clinicaltrials.gov)

P1/2, N=29, Terminated, Immunocore Ltd | N=63 --> 29

over 3 years ago

Enrollment change

CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)

HLA-A*02:01

IMCnyeso

over4years

Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers (clinicaltrials.gov)

P1/2, N=63, Terminated, Immunocore Ltd | Active, not recruiting --> Terminated; Strategic decision to stop development and not based on any safety concerns

over 4 years ago

Clinical • Trial termination

CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)

HLA-A*02:01

IMCnyeso

over4years

Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers (clinicaltrials.gov)

P1/2, N=63, Active, not recruiting, Immunocore Ltd | Recruiting --> Active, not recruiting

over 4 years ago

Clinical • Enrollment closed

CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)

IMCnyeso